{"id":"mlc601","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Shahid Beheshti University","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":["NeuroAid"],"company":"Shahid Beheshti University","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MLC601","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:01:10.998158+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:01:24.438082+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:01:16.397758+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MLC601","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:01:17.163550+00:00"}},"allNames":["mlc601"],"offLabel":[],"synonyms":[],"timeline":[],"aiSummary":"MLC601, developed by Shahid Beheshti University, is a marketed drug with an unknown mechanism of action. The key composition patent for MLC601 is set to expire in 2028, which may provide a period of market exclusivity. The primary risk is the lack of a defined mechanism of action, which could limit its adoption and regulatory support.","approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"A detailed technical explanation of mlc601's mechanism of action is not available due to the lack of information on its target, drug class, or binding characteristics."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=mlc601","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=mlc601","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:31:16.655107","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:01:24.438154+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"mlc601","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02537899","phase":"PHASE4","title":"Spinal Cord Injury - Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD","status":"COMPLETED","sponsor":"Moleac Pte Ltd.","startDate":"2015-04","conditions":["Spinal Cord Injury"],"enrollment":30,"completionDate":"2023-09-20"},{"nctId":"NCT02536079","phase":"","title":"NeuroAiD Safe Treatment Registry","status":"UNKNOWN","sponsor":"CHIMES Society","startDate":"2014-06","conditions":["Brain Injury","NeuroAiD Use"],"enrollment":2000,"completionDate":"2025-12"},{"nctId":"NCT03038035","phase":"PHASE2","title":"The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2016-12","conditions":["Alzheimer Disease"],"enrollment":150,"completionDate":"2019-06"},{"nctId":"NCT01696123","phase":"PHASE2","title":"Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2011-01","conditions":["Alzheimer Disease"],"enrollment":125,"completionDate":"2012-08"},{"nctId":"NCT01336153","phase":"PHASE4","title":"Clinical Study to Investigate the Safety and Efficacy of MLC601 in 150 Iranian Patients After Stroke","status":"COMPLETED","sponsor":"Shahid Beheshti University","startDate":"2009-08","conditions":["Stroke"],"enrollment":150,"completionDate":"2010-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Shahid Beheshti University","relationship":"Original Developer"}],"publicationCount":49,"therapeuticAreas":["Other"],"biosimilarFilings":[],"originalDeveloper":"Shahid Beheshti University","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"MLC601","companyName":"Shahid Beheshti University","companyId":"shahid-beheshti-university","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:01:24.438154+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}